E. Sigurdsson

发表

Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice.

D. Holtzman, Yong Ji, B. Permanne, 2001, Journal of Alzheimer's disease : JAD.

Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging

Thomas Wisniewski, Cheuk Y. Tang, Youssef Zaim Wadghiri, 2003, Magnetic resonance in medicine.

A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice

Thomas Wisniewski, Daniel H. Turnbull, Lisa Mosconi, 2008, Neurobiology of Aging.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Ayodeji A. Asuni, Einar M. Sigurdsson, D. Quartermain, 2007, The Journal of Neuroscience.

Infectivity of amyloid diseases.

E. Sigurdsson, T. Wisniewski, B. Frangione, 2002, Trends in molecular medicine.

β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy

Claudio Soto, Einar M. Sigurdsson, E. Sigurdsson, 1998, Nature Medicine.

A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

D. Holtzman, E. Sigurdsson, T. Wisniewski, 2004, The American journal of pathology.

In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI.

E. Sigurdsson, A. Bertrand, Y. Wadghiri, 2018, Methods in molecular biology.

NON-INVASIVE EVALUATION OF TAU TARGETED IMMUNOTHERAPY : A TRACT-TRACING BOLUS MEMRI STUDY

E. Sigurdsson, Y. Wadghiri, D. Hoang, 2011 .

Local and distant histopathological effects of unilateral amyloid-β 25–35 injections into the amygdala of young F344 rats

E. Sigurdsson, John M. Lee, S. Lorens, 1996, Neurobiology of Aging.

Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages.

D. Quartermain, E. Sigurdsson, T. Wisniewski, 2006, The European journal of neuroscience.

An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-β Derivatives

D. Quartermain, E. Sigurdsson, T. Wisniewski, 2004, The Journal of Neuroscience.

Distinct properties of wild‐type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type

E. Sigurdsson, C. Soto, M. Calero, 2001, Journal of neurochemistry.

Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.

E. Sigurdsson, 2018, Journal of Alzheimer's disease : JAD.

Tau Immunotherapy and Imaging

E. Sigurdsson, 2013, Neurodegenerative Diseases.

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

D. Quartermain, E. Sigurdsson, A. Boutajangout, 2010, The Journal of Neuroscience.

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

E. Sigurdsson, P. Davies, A. Boutajangout, 2011, Journal of neurochemistry.

Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.

S. Trouche, E. Sigurdsson, T. Wisniewski, 2009, Vaccine.

Therapeutics in Alzheimer's and prion diseases.

E. Sigurdsson, T. Wisniewski, D. Brown, 2001, Biochemical Society transactions.

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

E. Sigurdsson, P. Krishnamurthy, Yan Deng, 2011, Front. Psychiatry.

Current Status of Clinical Trials on Tau Immunotherapies

E. Sigurdsson, Changyi Ji, 2021, Drugs.

Tau immunotherapies: Lessons learned, current status and future considerations

E. Sigurdsson, L. A. Sandusky-Beltran, Leslie A. Sandusky-Beltran, 2020, Neuropharmacology.

Structural characterization of monoclonal antibodies targeting C-terminal Ser404region of phosphorylated tau protein.

E. Sigurdsson, X. Kong, E. Congdon, 2019 .

Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein

E. Sigurdsson, X. Kong, E. Congdon, 2019, mAbs.

Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders.

D. Quartermain, E. Sigurdsson, A. Boutajangout, 2012, Methods in molecular biology.

Immunization for Alzheimer's disease

E. Sigurdsson, T. Wisniewski, B. Frangione, 2002 .

Amyloid-β Injection in Rat Amygdala Alters Tau Protein but Not mRNA Expression

E. Sigurdsson, C. Chambers, John M. Lee, 2000, Experimental Neurology.

Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau

E. Sigurdsson, J. Falsig, L. Pedersen, 2018, Alzheimer's & dementia.

Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach

E. Sigurdsson, J. T. Pedersen, S. Rasool, 2016, Alzheimer's & Dementia.

Harnessing the immune system for treatment and detection of tau pathology.

E. Sigurdsson, E. Congdon, Senthilkumar Krishnaswamy, 2014, Journal of Alzheimer's disease : JAD.

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance*

E. Sigurdsson, E. Congdon, Jiaping Gu, 2013, The Journal of Biological Chemistry.

Immunotherapy for Tauopathies

E. Sigurdsson, Jiaping Gu, 2011, Journal of Molecular Neuroscience.

Promising developments in prion immunotherapy

E. Sigurdsson, T. Wisniewski, 2005, Expert review of vaccines.

VISUAL PROCFSSING IN ALZHEIMER'S DISEASE

M. Brigell, E. Sigurdsson, G. Celesia, 1995 .

Visual Processing in Alzheimer’s Disease

A. Villa, M. Brigell, E. Sigurdsson, 1995 .

Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model

E. Sigurdsson, E. Congdon, Qian Wu, 2020, Frontiers in Neurology.

Diminished A β Burden in Tg2576 Mice Following a Prophylactic Oral Immunization with a Salmonella-based A β Derivative Vaccine

D. Quartermain, E. Sigurdsson, B. Frangione, 2010 .

Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.

D. Quartermain, E. Sigurdsson, T. Wisniewski, 2009, Journal of Alzheimer's disease : JAD.

Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

E. Sigurdsson, M. Kuo, E. Congdon, 2022, EBioMedicine.

Amyloid Proteins

E. Sigurdsson, M. Gasset, M. Calero, 2018, Methods in Molecular Biology.

New directions towards safer and effective vaccines for Alzheimer's disease.

E. Sigurdsson, F. Goñi, 2005, Current opinion in molecular therapeutics.

Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging

E. Sigurdsson, Qian Wu, Jiaping Gu, 2018, EBioMedicine.

Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.

E. Sigurdsson, 2018, Journal of Alzheimer's disease : JAD.

Tau as a therapeutic target for Alzheimer's disease.

E. Sigurdsson, A. Boutajangout, P. Krishnamurthy, 2011, Current Alzheimer research.

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

E. Sigurdsson, S. Rasool, E. Congdon, 2016, Molecular Neurodegeneration.

Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue.

E. Sigurdsson, Hameetha B. Rajamohamedsait, 2012, Methods in molecular biology.

Tau-targeting therapies for Alzheimer disease

E. Sigurdsson, E. Congdon, 2018, Nature Reviews Neurology.

Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging

Thomas Wisniewski, Clifford R. Jack, Bret J. Borowski, 2002, Neurobiology of Disease.

Therapeutic applications of antibodies in non-infectious neurodegenerative diseases.

E. Sigurdsson, P. Krishnamurthy, 2011, New biotechnology.

Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.

E. Sigurdsson, E. Congdon, Yixiang Jiang, 2021, Seminars in cell & developmental biology.

Response: Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model

E. Sigurdsson, L. A. Sandusky-Beltran, Begoña Gamallo-Lana, 2020, Frontiers in Aging Neuroscience.

Amyloid fibril formation by macrophage migration inhibitory factor.

E. Sigurdsson, L. Leng, R. Bucala, 2005, Biochemical and biophysical research communications.

Specific Amyloid β Clearance by a Catalytic Antibody Construct*

E. Sigurdsson, R. Friedland, Y. Nishiyama, 2015, The Journal of Biological Chemistry.

Alzheimer's therapy development: A few points to consider.

E. Sigurdsson, 2019, Progress in molecular biology and translational science.

Murine models of Alzheimer's disease and their use in developing immunotherapies.

E. Sigurdsson, T. Wisniewski, 2010, Biochimica et biophysica acta.

High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice

E. Sigurdsson, T. Wisniewski, F. Goñi, 2008, Neuroscience.

Therapeutic approaches for prion and Alzheimer's diseases

E. Sigurdsson, T. Wisniewski, 2007, The FEBS journal.

Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

E. Sigurdsson, X. Kong, T. Neubert, 2019, EBioMedicine.

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology*

E. Sigurdsson, E. Congdon, Jiaping Gu, 2013, The Journal of Biological Chemistry.

Bilateral Injections of Amyloid-β 25-35 into the Amygdala of Young Fischer Rats: Behavioral, Neurochemical, and Time Dependent Histopathological Effects

E. Sigurdsson, S. Lorens, M. Hejna, 1997, Neurobiology of Aging.

Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology

E. Sigurdsson, T. Wisniewski, L. Morelli, 2006, Journal of neuropathology and experimental neurology.

β-Amyloid 25–35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: Behavioral, neurochemical and histological effects

E. Sigurdsson, S. Lorens, M. Hejna, 1995, Behavioural Brain Research.

Immunization delays the onset of prion disease in mice.

E. Sigurdsson, T. Wisniewski, David R. Brown, 2002, The American journal of pathology.

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.

B Frangione, E. Sigurdsson, T. Wisniewski, 2001, The American journal of pathology.

Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory

A. Palmeri, L. Honig, E. Sigurdsson, 2016, Scientific Reports.

Copper Chelation Delays the Onset of Prion Disease*

E. Sigurdsson, T. Wisniewski, David R. Brown, 2003, Journal of Biological Chemistry.

In Vivo Magnetic Resonance of Amyloid Plaques in Alzheimer’s Disease Model Mice

Thomas Wisniewski, Daniel H. Turnbull, Cheuk Y. Tang, 2004 .

Anti-prion antibodies for prophylaxis following prion exposure in mice

E. Sigurdsson, T. Wisniewski, R. Carp, 2003, Neuroscience Letters.

Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRI

Dmitry S. Novikov, Umer Khan, Anne Bertrand, 2013, NeuroImage.

Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease

T. Sacktor, S. Mirra, E. Sigurdsson, 2011, Acta Neuropathologica.

A safer vaccine for Alzheimer’s disease?

E. Sigurdsson, T. Wisniewski, B. Frangione, 2002, Neurobiology of Aging.

Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice

E. Sigurdsson, S. Rasool, Hameetha B. Rajamohamedsait, 2017, Scientific Reports.

Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments

Helen Wong, E. Sigurdsson, T. Franke, 2013, Acta neuropathologica communications.

Tau Immunotherapy

E. Sigurdsson, 2015, Neurodegenerative Diseases.

Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imaging

Thomas Wisniewski, D. Quartermain, E. Sigurdsson, 2008, Journal of Neuroscience Research.

Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages

D. Quartermain, E. Sigurdsson, T. Wisniewski, 2006, The European journal of neuroscience.

Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein

E. Sigurdsson, L. Pedersen, X. Kong, 2018, Scientific Reports.

Tau immunotherapy for Alzheimer's disease.

E. Sigurdsson, J. T. Pedersen, 2015, Trends in molecular medicine.

Antibody-Derived In Vivo Imaging of Tau Pathology

E. Sigurdsson, Senthilkumar Krishnaswamy, Hameetha B. Rajamohamedsait, 2014, The Journal of Neuroscience.

Mechanistic studies of antibody mediated clearance of tau aggregates using an ex vivo brain slice model

E. Sigurdsson, P. Mathews, P. Krishnamurthy, 2010, Alzheimer's & Dementia.

Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

E. Sigurdsson, 2008, Journal of Alzheimer's disease : JAD.

Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models

E. Sigurdsson, H. Ryoo, Huai-Wei Huang, 2020, Neurobiology of Disease.

Alzheimer’s disease research progress in Australia: The Alzheimer’s Association International Conference Satellite Symposium in Sydney

K. Blennow, M. Carrillo, C. Rowe, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model

E. Sigurdsson, Hameetha B. Rajamohamedsait, L. A. Sandusky-Beltran, 2020, Frontiers in Aging Neuroscience.

Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice

W. Gan, Wei Li, E. Sigurdsson, 2020, Neurobiology of Disease.

Immunotherapy for conformational diseases.

E. Sigurdsson, 2006, Current pharmaceutical design.

Mucosal vaccination delays or prevents prion infection via an oral route

E. Sigurdsson, T. Wisniewski, R. Carp, 2005, Neuroscience.

Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

E. Sigurdsson, 2009, Current Alzheimer research.

Immunization treatment approaches in Alzheimer’s and prion diseases

E. Sigurdsson, T. Wisniewski, 2002, Current neurology and neuroscience reports.

A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice

Thomas Wisniewski, Paul M. Mathews, Stephen D. Schmidt, 2004 .

In Vivo Reversal of Amyloid‐β Lesions in Rat Brain

B. Permanne, E. Sigurdsson, T. Wisniewski, 2000 .

In vivo reversal of amyloid-beta lesions in rat brain.

B. Permanne, E. Sigurdsson, T. Wisniewski, 2000, Journal of neuropathology and experimental neurology.

Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds

S. Trouche, M. Dhenain, E. Sigurdsson, 2013, Neurobiology of Aging.

In vivo magnetic resonance imaging of amyloid-β plaques in mice.

E. Sigurdsson, T. Wisniewski, Y. Wadghiri, 2012, Methods in molecular biology.

Magnetic resonance imaging of amyloid plaques in transgenic mice.

Thomas Wisniewski, Youssef Zaim Wadghiri, Daniel H Turnbull, 2005, Methods in molecular biology.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

Antibody response and plasma A β 1-40 levels in young Microcebus murinus primates immunized with A β 1-42 and its derivatives

S. Trouche, E. Sigurdsson, B. Frangione, 2009 .

Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice

E. Sigurdsson, Senthilkumar Krishnaswamy, Hameetha B. Rajamohamedsait, 2016, Front. Endocrinol..

Amyloid-beta injection in rat amygdala alters tau protein but not mRNA expression.

E. Sigurdsson, C. Chambers, S. Lorens, 2000, Experimental neurology.

Single-domain antibody–based noninvasive in vivo imaging of α-synuclein or tau pathology

E. Sigurdsson, M. Kuo, E. Congdon, 2023, Science advances.

Live Imaging of Pathological Tau Protein and Tau Antibodies in a Neuron-Like Cellular Model.

E. Sigurdsson, Yan Deng, D. B. Shamir, 2018, Methods in molecular biology.

Amyloid proteins : methods and protocols

Einar M. Sigurdsson, E. Sigurdsson, M. Gasset, 2005 .

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

E. Sigurdsson, Yu-Shin Ding, D. Sehlin, 2023, Frontiers in Nuclear Medicine.

Amyloid Proteins

E. Sigurdsson, 2005, Methods in Molecular Biology™.

P3‐427: Passive tau immunotherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy

E. Sigurdsson, P. Davies, A. Boutajangout, 2010 .

Conformation as therapeutic target in the prionoses and other neurodegenerative conditions.

E. Sigurdsson, T. Wisniewski, B. Frangione, 2001, Methods in molecular medicine.

Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments

E. Sigurdsson, T. Franke, P. Cain, 2013, Acta neuropathologica communications.

Immunotherapy targeting Alzheimer's phospho-tau epitope within the microtubule binding region of tau clears pathological tau and prevents functional decline in a mouse model of tauopathy

E. Sigurdsson, A. Boutajangout, P. Krishnamurthy, 2009, Alzheimer's & Dementia.

O4-04-04: Tau immunotherapy prevents cognitive decline and clears pathological Tau in a tangle mouse model

D. Quartermain, E. Sigurdsson, A. Boutajangout, 2008, Alzheimer's & Dementia.

O4-01-05: Presenilin 1 mutation promotes Tau phosphorylation and aggregation in a novel Alzheimer's disease mouse model

E. Sigurdsson, T. Wisniewski, J. Brion, 2008, Alzheimer's & Dementia.

Fab/epitope complex of mouse monoclonal antibody 8B2 targeting a non-phosphorylated tau epitope.

E. Sigurdsson, X. Kong, E. Congdon, 2019 .

Tau Immunotherapy

E. Sigurdsson, 2015, Neurodegenerative Diseases.

Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders.

D. Quartermain, E. Sigurdsson, A. Boutajangout, 2012, Methods in molecular biology.

Targeting hyperphosphorylated tau protein with a monoclonal antibody at an advanced stage of tau pathology improves cognition in a mouse model

E. Sigurdsson, A. Boutajangout, Veronica Gonzalez, 2011, Alzheimer's & Dementia.